TY - JOUR
T1 - Association of Distinct Fine Specificities of Anti−Citrullinated Peptide Antibodies With Elevated Immune Responses to Prevotella intermedia in a Subgroup of Patients With Rheumatoid Arthritis and Periodontitis
AU - Schwenzer, Anja
AU - Quirke, Anne Marie
AU - Marzeda, Anna M.
AU - Wong, Alicia
AU - Montgomery, Anna B.
AU - Sayles, Harlan R.
AU - Eick, Sigrun
AU - Gawron, Katarzyna
AU - Chomyszyn-Gajewska, Maria
AU - Łazarz-Bartyzel, Katarzyna
AU - Davis, Simon
AU - Potempa, Jan
AU - Kessler, Benedikt M.
AU - Fischer, Roman
AU - Venables, Patrick J.
AU - Payne, Jeffrey B.
AU - Mikuls, Ted R.
AU - Midwood, Kim S.
N1 - Funding Information:
Supported by the Innovative Medicines Initiative (BTCure grant 115142-2), the Kennedy Trust for Rheumatology Research (grant AZRYXS00), and the US Department of Veterans Affairs (Clinical Science Research and Development Merit Award CX000896). Dr. Gawron’s work was supported by the National Science Centre, Poland (grant 2012/07/B/NZ6/03524). Dr. Potempa’s work was supported by the NIH (National Institute of Dental and Craniofacial Research grant R01-DE-022597). Drs. Kessler and Fischer’s work was supported by the Kennedy Trust Fund. Dr. Mikuls’ work was supported by the NIH (National Institute of General Medical Sciences grant U54-GM-115458). Dr. Midwood’s work was supported by an Arthritis Research UK Senior Fellowship (grant 20003).
Publisher Copyright:
© 2017 The Authors. Arthritis & Rheumatology published by Wiley Periodicals, Inc. on behalf of American College of Rheumatology.
PY - 2017/12
Y1 - 2017/12
N2 - Objective: In addition to the long-established link with smoking, periodontitis (PD) is a risk factor for rheumatoid arthritis (RA). This study was undertaken to elucidate the mechanism by which PD could induce antibodies to citrullinated peptides (ACPAs), by examining the antibody response to a novel citrullinated peptide of cytokeratin 13 (CK-13) identified in gingival crevicular fluid (GCF), and comparing the response to 4 other citrullinated peptides in patients with RA who were well-characterized for PD and smoking. Methods: The citrullinomes of GCF and periodontal tissue from patients with PD were mapped by mass spectrometry. ACPAs of CK13 (cCK13), tenascin-C (cTNC5), vimentin (cVIM), α-enolase (CEP-1), and fibrinogen β (cFIBβ) were examined by enzyme-linked immunosorbent assay in patients with RA (n = 287) and patients with osteoarthritis (n = 330), and cross-reactivity was assessed by inhibition assays. Results: A novel citrullinated peptide cCK13-1 (444TSNASGR-Cit-TSDV-Cit-RP458) identified in GCF exhibited elevated antibody responses in RA patients (24%). Anti–cCK13-1 antibody levels correlated with anti–cTNC5 antibody levels, and absorption experiments confirmed this was not due to cross-reactivity. Only anti–cCK13-1 and anti-cTNC5 were associated with antibodies to the periodontal pathogen Prevotella intermedia (P = 0.05 and P = 0.001, respectively), but not with antibodies to Porphyromonas gingivalis arginine gingipains. Levels of antibodies to CEP-1, cFIBβ, and cVIM correlated with each other, and with smoking and shared epitope risk factors in RA. Conclusion: This study identifies 2 groups of ACPA fine specificities associated with different RA risk factors. One is predominantly linked to smoking and shared epitope, and the other links anti–cTNC5 and cCK13-1 to infection with the periodontal pathogen P intermedia.
AB - Objective: In addition to the long-established link with smoking, periodontitis (PD) is a risk factor for rheumatoid arthritis (RA). This study was undertaken to elucidate the mechanism by which PD could induce antibodies to citrullinated peptides (ACPAs), by examining the antibody response to a novel citrullinated peptide of cytokeratin 13 (CK-13) identified in gingival crevicular fluid (GCF), and comparing the response to 4 other citrullinated peptides in patients with RA who were well-characterized for PD and smoking. Methods: The citrullinomes of GCF and periodontal tissue from patients with PD were mapped by mass spectrometry. ACPAs of CK13 (cCK13), tenascin-C (cTNC5), vimentin (cVIM), α-enolase (CEP-1), and fibrinogen β (cFIBβ) were examined by enzyme-linked immunosorbent assay in patients with RA (n = 287) and patients with osteoarthritis (n = 330), and cross-reactivity was assessed by inhibition assays. Results: A novel citrullinated peptide cCK13-1 (444TSNASGR-Cit-TSDV-Cit-RP458) identified in GCF exhibited elevated antibody responses in RA patients (24%). Anti–cCK13-1 antibody levels correlated with anti–cTNC5 antibody levels, and absorption experiments confirmed this was not due to cross-reactivity. Only anti–cCK13-1 and anti-cTNC5 were associated with antibodies to the periodontal pathogen Prevotella intermedia (P = 0.05 and P = 0.001, respectively), but not with antibodies to Porphyromonas gingivalis arginine gingipains. Levels of antibodies to CEP-1, cFIBβ, and cVIM correlated with each other, and with smoking and shared epitope risk factors in RA. Conclusion: This study identifies 2 groups of ACPA fine specificities associated with different RA risk factors. One is predominantly linked to smoking and shared epitope, and the other links anti–cTNC5 and cCK13-1 to infection with the periodontal pathogen P intermedia.
UR - http://www.scopus.com/inward/record.url?scp=85033213709&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85033213709&partnerID=8YFLogxK
U2 - 10.1002/art.40227
DO - 10.1002/art.40227
M3 - Article
C2 - 29084415
AN - SCOPUS:85033213709
VL - 69
SP - 2303
EP - 2313
JO - Arthritis and Rheumatology
JF - Arthritis and Rheumatology
SN - 2326-5191
IS - 12
ER -